Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model

Gerlier L, Lamotte M, Greneche S, Lenne X, Carrat F, Weil-Olivier C, Damm O, Schwehm M, Eichner M (2017)
APPLIED HEALTH ECONOMICS AND HEALTH POLICY 15(2): 261-276.

Download
No fulltext has been uploaded. References only!
Journal Article | Original Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ;
Abstract
Objectives We estimated the epidemiological and economic impact of extending the French influenza vaccination programme from at-risk/elderly (>= 65 years) only to healthy children (2-17 years). Methods A deterministic, age-structured, dynamic transmission model was used to simulate the transmission of influenza in the French population, using the current vaccination coverage with trivalent inactivated vaccine (TIV) in at-risk/elderly individuals (current strategy) or gradually extending the vaccination to healthy children (aged 2-17 years) with intranasal, quadrivalent live-attenuated influenza vaccine (QLAIV) from current uptake up to 50% (evaluated strategy). Epidemiological, medical resource use and cost data were taken from international literature and country-specific information. The model was calibrated to the observed numbers of influenza-like illness visits/year. The 10-year number of symptomatic cases of confirmed influenza and direct medical costs ('all-payer') were calculated for the 0-17-(direct and indirect effects) and >= 18-year-old (indirect effect). The incremental cost-effectiveness ratio (ICER) was calculated for the total population, using a 4% discount rate/year. Results Assuming 2.3 million visits/year and 1960 deaths/year, the model calibration yielded an all-year average basic reproduction number (R-0) of 1.27. In the population aged 0-17 years, QLAIV prevented 865,000 influenza cases/year (58.4%), preventing 10-year direct medical expenses of (sic)374 million. In those aged >= 18 years with unchanged TIV coverage, 1.2 million cases/year were averted (27.6%) via indirect effects (additionally prevented expenses, (sic)457 million). On average, 613 influenza-related deaths were averted annually overall. The ICER was (sic)18,001/life-year gained. The evaluated strategy had a 98% probability of being cost-effective at a (sic)31,000/life-year gained threshold. Conclusions The model demonstrated strong direct and indirect benefits of protecting healthy children against influenza with QLAIV on public health and economic outcomes in France.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Gerlier L, Lamotte M, Greneche S, et al. Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2017;15(2):261-276.
Gerlier, L., Lamotte, M., Greneche, S., Lenne, X., Carrat, F., Weil-Olivier, C., Damm, O., et al. (2017). Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 15(2), 261-276. doi:10.1007/s40258-016-0296-4
Gerlier, L., Lamotte, M., Greneche, S., Lenne, X., Carrat, F., Weil-Olivier, C., Damm, O., Schwehm, M., and Eichner, M. (2017). Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 15, 261-276.
Gerlier, L., et al., 2017. Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 15(2), p 261-276.
L. Gerlier, et al., “Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model”, APPLIED HEALTH ECONOMICS AND HEALTH POLICY, vol. 15, 2017, pp. 261-276.
Gerlier, L., Lamotte, M., Greneche, S., Lenne, X., Carrat, F., Weil-Olivier, C., Damm, O., Schwehm, M., Eichner, M.: Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 15, 261-276 (2017).
Gerlier, L., Lamotte, M., Greneche, S., Lenne, X., Carrat, F., Weil-Olivier, C., Damm, Oliver, Schwehm, M., and Eichner, M. “Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model”. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 15.2 (2017): 261-276.
This data publication is cited in the following publications:
This publication cites the following data publications:

1 Citation in Europe PMC

Data provided by Europe PubMed Central.

Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016.
Visseaux B, Burdet C, Voiriot G, Lescure FX, Chougar T, Brugière O, Crestani B, Casalino E, Charpentier C, Descamps D, Timsit JF, Yazdanpanah Y, Houhou-Fidouh N., PLoS One 12(7), 2017
PMID: 28708843

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 27943165
PubMed | Europe PMC

Search this title in

Google Scholar